Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis. 
Peritoneal metastasis (PM) has traditionally been approached with therapeutic nihilism.  The evolution of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) over the last two decades, however, has caused a paradigm shift in treatment for PM.  This modality is rapidly gaining acceptance as standard of care for PM from various cancers.  This article reviews the current literature regarding the use of CRS/HIPEC for PM from the most common intra-abdominal malignancies.